C. Lee

V. Gebski, I. Marschner, L. Sequist, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Evaluation of Phase II Trial Design in Advanced Pancreatic Cancer.

I. Marschner, R. Simes, D. Goldstein, 2019, Pancreas.

Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.

V. Gebski, G. Kristensen, P. Witteveen, 2017, Gynecologic oncology.

1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study

E. Felip, B. Cho, R. Knoblauch, 2021, Annals of Oncology.

Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations.

Jie Yang, N. Pavlakis, Y. Yatabe, 2022, Clinical lung cancer.

Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials

I. Marschner, M. Friedlander, J. Simes, 2020, JAMA network open.

Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer.

V. Gebski, I. Marschner, S. Loi, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007–2016)

B. Kiely, R. Simes, S. Pearson, 2019, British Journal of Cancer.

Efficacy of immune checkpoint inhibitors in older adults with advanced stage cancers: A meta-analysis.

I. Marschner, M. Friedlander, L. Kasherman, 2020, Journal of geriatric oncology.

VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer

V. Gebski, J. Mariadason, J. Simes, 2022, Scientific Reports.

OA04.04 Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer

N. Girard, Dohoung Kim, B. Cho, 2021 .

Molecular and clinical predictors of improvement in progression‐free survival with maintenance PARP inhibitor therapy in women with platinum‐sensitive, recurrent ovarian cancer: A meta‐analysis

Ping Wang, J. Ledermann, R. Glasspool, 2021, Cancer.

Progression-free survival (PFS) as a surrogate end point for overall survival (OS) in first-line treatment of advanced epithelial ovarian cancer (EOC).

I. Marschner, M. Chatfield, J. Simes, 2012 .

Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting.

V. Gebski, M. Friedlander, S. Lord, 2021, European journal of cancer.

The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis

S. Loi, M. Friedlander, R. Finn, 2018, Breast Cancer Research and Treatment.

Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy.

V. Gebski, M. Friedlander, R. Largillier, 2019, European journal of cancer.

Molecular biomarkers to individualise treatment: assessing the evidence

R. Simes, A. Coates, S. Lord, 2009, The Medical journal of Australia.

Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone

V. Gebski, R. Simes, A. Coates, 2013, SpringerPlus.

Pre‐ and on‐treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non–small cell lung cancer

I. Marschner, S. Lord, T. John, 2022, Cancer.

Cardiac assessment in Australian patients receiving (neo)adjuvant trastuzumab for HER2-positive early breast cancer: a population-based study

B. Kiely, R. Simes, S. Pearson, 2021, Breast Cancer Research and Treatment.

When do patient reported quality of life indicators become prognostic in breast cancer?

J. Bernhard, A. Coates, J. Simes, 2018, Health and Quality of Life Outcomes.

When is a GIST not a GIST? A case report of synchronous metastatic gastrointestinal stromal tumor and fibromatosis

D. Goldstein, Chee Khoon Lee, A. Hadley, 2009, World journal of surgical oncology.

Are clinical trial eligibility criteria representative of older patients with lung cancer? A population-based data linkage study.

R. Simes, S. Pearson, T. John, 2021, Journal of geriatric oncology.

85O_PRPatient-reported symptoms and impact of treatment with osimertinib vs chemotherapy for advanced non-small cell lung cancer

T. Mok, S. Novello, A. Templeton, 2017 .

Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial.

V. Gebski, I. Vergote, J. Sehouli, 2015, Gynecologic oncology.

Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial.

S. Novello, Chee Khoon Lee, H. Mann, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib.

J. Verweij, H. Joensuu, R. Maki, 2015, European journal of cancer.

Does chemotherapy improve survival in muscle-invasive bladder cancer (MIBC)? A systematic review and meta-analysis (MA) of randomized controlled trials (RCT).

M. Stockler, A. Tjokrowidjaja, C. Lee, 2013 .

Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer

R. Hettle, Chee Khoon Lee, C. McCrea, 2021, Therapeutic advances in medical oncology.

Abstract S1-10: Clinical implications of somatic mutations in post-menopausal early-stage estrogen receptor (ER)-positive HER2-negative breast cancer (BC): Results from the BIG 1-98 study

S. Loi, P. Savas, G. Viale, 2017 .

Alpelisib monotherapy for PI3K-altered, pre-treated advanced breast cancer: a phase 2 study.

S. Loi, S. Dawson, P. Savas, 2022, Cancer discovery.

Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Ying Cheng, C. Chiu, P. Janne, 2022, Cancer discovery.

Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).

N. Girard, Keunchil Park, Dong-Wan Kim, 2020 .

Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.

A. Oza, M. Friedlander, N. Colombo, 2022, Gynecologic oncology.

Correction: Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007–2016)

B. Kiely, R. Simes, S. Pearson, 2019, British Journal of Cancer.

Correlation of phase 2 trials (Ph2t) results with outcomes of phase 3 trials (Ph3t) of investigational agents (IA) in locally advanced and metastatic pancreas cancer (LAMPC).

I. Marschner, D. Goldstein, J. Simes, 2017 .

Generalizability of immune checkpoint inhibitor trials to real-world patients with advanced non-small cell lung cancer.

R. Simes, S. Pearson, Chee Khoon Lee, 2022, Lung cancer.

Performance of four published risk models to predict sentinel lymph-node involvement in Australian women with early breast cancer.

V. Gebski, G. Farshid, S. Lord, 2018, Breast.

Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis.

T. Mok, Yi-long Wu, K. Goto, 2021, Lung cancer.

The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy

V. Gebski, R. Motzer, S. Clarke, 2020, Acta oncologica.

Development of a nomogram to predict overall survival in patients with locally advanced or metastatic gastrointestinal stromal tumor receiving first-line treatment with imatinib.

D. Goldstein, G. McArthur, D. Yip, 2010 .

Benchmarking single-arm studies against historical controls from non-small cell lung cancer trials – an empirical analysis of bias

I. Marschner, Chee Khoon Lee, R. Asher, 2020, Acta oncologica.

Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer

M. Reni, J. Tabernero, D. V. Von Hoff, 2020, Pancreas.

Translating Clinical Trial Evidence to Routine Practice-How Do We Overcome the Barriers?

Chee Khoon Lee, Monica Tang, C. Lee, 2022, JAMA oncology.

AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort.

P. Jänne, Y. Ohe, S. Ramalingam, 2015 .

Testing for EGFR Variants in Pleural and Pericardial Effusion Cell-free DNA in Patients With Non-Small Cell Lung Cancer.

T. Mok, W. Gai, R. Yeung, 2022, JAMA oncology.

Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer

B Richter, I Vergote, V. Gebski, 2011, British Journal of Cancer.

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer

S. Clarke, D. Goldstein, B. Iacopetta, 2009, British Journal of Cancer.

A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer.

V. Gebski, R. Simes, J. Ledermann, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Where have we gone wrong? Phase II trials (Ph2t) do not inform the results of phase III trials (Ph3t) in platinum resistant ovarian cancer (PROC).

Julia Chen, M. Friedlander, S. Lord, 2016 .

Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D‐CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials

R. Simes, P. Roepman, H. Gelderblom, 2023, International journal of cancer.

The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial

J. Mariadason, P. Wirapati, P. Savas, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Increase in Cholesterol Predicts Survival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus

I. Marschner, R. Simes, B. Egleston, 2012, Clinical Cancer Research.

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.

V. Gebski, S. Thongprasert, D. Chu, 2013, Journal of the National Cancer Institute.

Management Paradigm of Central Nervous System Metastases in NSCLC: An Australian Perspective

Y. Soon, S. Siva, H. Le, 2023, JTO clinical and research reports.

The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial

J. Mariadason, P. Wirapati, P. Savas, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.

T. Price, N. Tebbutt, C. Murone, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.